Global Biosimilars Drug Market Growth (Status and Outlook) 2023-2029

Global Biosimilars Drug Market Growth (Status and Outlook) 2023-2029

The global Biosimilars Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Biosimilars Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Biosimilars Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Biosimilars Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Biosimilars Drug players cover Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.

LPI (LP Information)' newest research report, the “Biosimilars Drug Industry Forecast” looks at past sales and reviews total world Biosimilars Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilars Drug sales for 2023 through 2029. With Biosimilars Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilars Drug industry.

This Insight Report provides a comprehensive analysis of the global Biosimilars Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilars Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilars Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilars Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilars Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilars Drug market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Monoclonal Antibodies
Insulin
Others

Segmentation by application
Hospital
Retail Pharmacy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Celltrion
Pfizer
Novartis
Dr Reddy’s
Celgen Biopharma
Eli Lilly
Sanofi
Geropharm
Biocon
Wockhardt

Please note: The report will take approximately 2 business days to prepare and deliver.